Arkin Holdings

Newleos Therapeutics is a stealth-mode biotechnology company focused on developing safer and more effective treatments for neuropsychiatric disorders, aiming to improve mental health outcomes.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Revisto is a technology company that specializes in streamlining the medical, legal, and regulatory review process for pharmaceutical marketing materials. Utilizing AI, their platform accelerates the release time of these materials, reduces costs, and mitigates compliance risks. It automates the review process, provides content recommendations based on historical data, and ensures adherence to regulatory requirements.

Phytolon Ltd is a company based in Misgav, Israel, specializing in the development of natural food colorants. Founded in 2000, Phytolon utilizes a novel fermentation technology that employs baker's yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach offers a healthy alternative to synthetic food dyes, providing food manufacturers with safe, cost-effective, and stable all-natural color solutions. The company's mission is to leverage scientific advancements to promote human health and environmental sustainability in the food industry.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Honeycomb, formerly known as Agilius, operates an insurance technology platform that specializes in real estate insurance services. Founded in 2019 and based in San Francisco, California, the company offers a streamlined online process for homeowners associations, property managers, developers, and building owners to purchase master insurance policies for condominium and apartment buildings in under three minutes. By leveraging advanced technologies such as aerial photography, computer vision, artificial intelligence, and machine learning, Honeycomb eliminates the need for on-site inspections, allowing users to obtain instant, hassle-free quotes and manage their policies efficiently. This innovative approach aims to bring simplicity and transparency to the real estate insurance market, providing significant cost savings for its clients.

Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company’s primary focus is on its lead asset, RE104, a proprietary serotonergic psychedelic compound designed as a fast-acting and durable antidepressant for patients experiencing postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which comprises compounds aimed at achieving more selective serotonin receptor activity with reduced psychoactivity, thereby broadening the potential applications for chronic treatment scenarios. The company seeks to address significant gaps in mental health care through innovative pharmacological approaches.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. It specializes in developing innovative therapies known as "nocions," which are designed to treat conditions resulting from neurogenic inflammation. These therapies selectively target activated nociceptors, the sensory neurons responsible for pain perception, by utilizing small molecule charged sodium channel blockers. This targeted approach aims to provide robust and sustained relief from serious conditions such as cough, itch, pain, and inflammation, addressing the limitations of traditional small molecule anesthetics.

Siftwell operates as a predictive analytics company in the healthcare sector, utilizing artificial intelligence and machine learning to analyze extensive datasets, including health plan data, claims, and social determinants of health. The company focuses on identifying members at high risk for rising costs, declining health, and potential churn. By enhancing data-driven decision-making, Siftwell enables clients to improve member health outcomes, reduce healthcare costs, and enhance quality metrics, ultimately fostering greater member retention. Their unique expertise combines technology with managed care, allowing for an effective approach to solving complex challenges in the healthcare industry.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

MadeRight is a company based in San Mateo, California, engaged in the manufacturing and sale of apparel, jewelry, and accessories, both domestically and internationally. Its product range includes a variety of clothing items such as tops, bottoms, jackets, outerwear, tees, sweaters, underwear, suits, shirts, jeans, and leather shoes, as well as cotton woven fabrics and specialty textiles. In addition to its apparel business, MadeRight specializes in sustainable packaging solutions through a natural additive derived from fungi grown on industrial waste. This innovative additive enhances the performance of bio-plastics, making them more scalable, affordable, and degradable. It improves the physical and functional properties of packaging materials, including attributes such as anti-microbial and heat resistance.

Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Revamp Medical, founded in 2016, is dedicated to addressing the critical unmet needs of patients suffering from acute heart failure. With over one million annual admissions in the United States and associated costs exceeding $65 billion, the company aims to provide an innovative solution through its patented temporary catheter, Doraya™. This device regulates vascular hemodynamics, particularly for patients experiencing diuretic resistance, by managing preload and reducing central venous pressure. This functionality enhances diuretic efficacy and facilitates progressive decongestion, thereby allowing cardiologists to effectively manage key hemodynamic parameters. Revamp Medical is supported by a skilled team with extensive experience in the medical technology sector, positioning the company to make a significant impact in the treatment of acute heart failure.

Pigmentum is an ag-tech company focused on developing a molecular technology platform that facilitates external gene activation in plants. This innovative platform enables the crossbreeding and assimilation of genetic elements, allowing agricultural companies to create unique seeds. By leveraging this technology, Pigmentum aims to enhance the production of natural compounds for the food, pharmaceutical, and cosmetic industries, thereby supporting high-scale production and offering diverse possibilities for live plants.

Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

Welcome Homes is an online platform designed to simplify the home building process for buyers. By streamlining the journey from land selection to customization and construction, the company allows individuals to transition from home buyers to home builders. Its platform offers a fully online experience, ensuring a seamless and transparent home-buying process. Users can save time and clearly understand their costs while having the opportunity to create a beautifully designed home in their desired location.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Virility Medical is focused on developing an innovative intimate skin patch aimed at addressing premature ejaculation, a common male sexual dysfunction. The patch is equipped with an electronic module that generates neuromuscular electrical stimulation, which is delivered transcutaneously to surrounding muscles. This technology enables users to effectively delay the onset of premature ejaculation, providing a discreet and non-invasive solution for men seeking to enhance their sexual performance.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Phytolon Ltd is a company based in Misgav, Israel, specializing in the development of natural food colorants. Founded in 2000, Phytolon utilizes a novel fermentation technology that employs baker's yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach offers a healthy alternative to synthetic food dyes, providing food manufacturers with safe, cost-effective, and stable all-natural color solutions. The company's mission is to leverage scientific advancements to promote human health and environmental sustainability in the food industry.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.

Fu-Gen is an independent power producer and renewable energy investor focused on developing and managing a network of renewable energy projects. The company specializes in creating greenfield initiatives and investing in various stages of project development, from pre-permit to operational phases, primarily in wind and solar energy. By building a diverse portfolio that includes solar, wind, and energy storage projects, Fu-Gen aims to optimize renewable energy assets and support the transition to a low carbon economy in Europe. The firm is committed to delivering sustainable returns to its investors while contributing to the growth of the renewable energy sector.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Mindspace Ltd. is a provider of high-end co-working office spaces and rooms, catering to a diverse clientele that includes entrepreneurs, freelancers, startups, and established enterprises. Founded in 2013 and headquartered in Tel Aviv, Israel, the company operates additional locations in cities such as Herzliya, Warsaw, London, Washington, San Francisco, Berlin, Hamburg, and Munich. Mindspace offers a range of flexible workspace solutions, including open spaces, private offices, meeting rooms, and event venues, designed to meet the varying needs of teams of all sizes. The company emphasizes beautifully designed environments and a personalized level of service, fostering enhanced employee engagement and a strong sense of community. With a presence in over 40 locations across 20 cities and 7 countries, Mindspace aims to redefine the workplace experience, accommodating the evolving ways in which people work and collaborate.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Lendbuzz, Inc. is a Boston-based company that operates an innovative car financing platform aimed at individuals with limited or no credit history, such as international students, foreign professionals, and expatriates. Founded in 2015, Lendbuzz uses machine learning algorithms and proprietary technology to assess the creditworthiness of consumers who are typically underserved by traditional financial institutions. By evaluating background information, including employment and educational history, the platform provides tailored car loans and financing solutions with favorable terms and low-interest rates. Lendbuzz partners with auto dealerships to enhance their offerings, allowing them to serve a more diverse clientele and close additional business opportunities. The company emphasizes a streamlined documentation process, making it easier for clients to access and manage their loans.

Laguna Health is a provider of AI-powered contextual care management services aimed at enhancing personalized care, particularly during hospital transitions. The company utilizes advanced artificial intelligence and natural language processing to deliver Conversational Care Intelligence, which enables care managers to respond more efficiently and consistently to individual needs. By offering real-time insights without the need for integration into existing platforms and workflows, Laguna Health empowers healthcare providers to deliver improved care outcomes more quickly. The effectiveness of its services is supported by published clinical research and validated results, demonstrating significant cost savings and productivity gains for care managers. Through its innovative technology, Laguna Health collaborates with national health plans and integrated delivery networks to enhance member outcomes and streamline care management processes.

Edocate is a developer of a medical simulation platform focused on chronic disease management and medical education. Its platform allows customers to create unique virtual patient cases across various therapeutic areas to engage healthcare professionals. By providing self-based learning tools for ongoing training and assessment, Edocate enables medical education providers to develop and distribute their own content efficiently. The platform also offers valuable insights into healthcare professional decision-making, clinical gaps, prescription patterns, guideline compliance, and patient outcomes, thereby enhancing the overall quality of healthcare training and education.

MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

BioSight Ltd., established in 1999 and headquartered in Lod, Israel, is a biopharmaceutical company specializing in the development of innovative cancer-targeted pro-drugs. It focuses on creating non-toxic conjugates like its cytarabine-asparagine conjugate for treating acute myeloid leukemia patients worldwide. BioSight's proprietary technology, S2DOT™, enables targeted drug release inside cancer cells, minimizing systemic toxicity compared to conventional chemotherapy treatments.

Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Pixellot is a sports media company based in Tel Aviv, Israel, specializing in automated video capture and production solutions for amateur and semi-professional sports events. Founded in 2014 by experts in video and media technology, Pixellot offers patented technology that streamlines production workflows using an unmanned multi-camera system covering the entire field. Advanced algorithms enable dynamic coverage of gameplay and highlight generation. The company streams over 11,000 live video hours monthly to fans, players, and coaches across various platforms. Pixellot has deployed more than 2,000 systems globally, serving minor leagues, high schools, youth academies, and top league clubs. Notable partners include ESPN, PlayOn Sports, Sporttotal.tv, STATS, SeeUPlay, and Hockey TV, as well as leading clubs such as Bayern Munich, Real Sociedad, AZ Alkmaar, and Maccabi Tel-Aviv.

Redpin Therapeutics, Inc. is a preclinical stage gene therapy company founded in 2017 and based in New York, New York. The company specializes in developing a proprietary chemogenetics platform for targeted cell therapies aimed at addressing intractable diseases of the nervous system. Redpin's innovative approach utilizes ion channels as neuromodulation tools, allowing for selective activation or inhibition of disease-causing neurons while preserving normal functioning cells. By controlling these neuronal circuits, Redpin enables physicians to precisely target dysfunctional neural activity associated with specific conditions. The company's technology integrates principles from synthetic biology, gene therapy, and traditional pharmacotherapy to advance its mission of addressing complex neurological disorders.

BioSight Ltd., established in 1999 and headquartered in Lod, Israel, is a biopharmaceutical company specializing in the development of innovative cancer-targeted pro-drugs. It focuses on creating non-toxic conjugates like its cytarabine-asparagine conjugate for treating acute myeloid leukemia patients worldwide. BioSight's proprietary technology, S2DOT™, enables targeted drug release inside cancer cells, minimizing systemic toxicity compared to conventional chemotherapy treatments.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Lendbuzz, Inc. is a Boston-based company that operates an innovative car financing platform aimed at individuals with limited or no credit history, such as international students, foreign professionals, and expatriates. Founded in 2015, Lendbuzz uses machine learning algorithms and proprietary technology to assess the creditworthiness of consumers who are typically underserved by traditional financial institutions. By evaluating background information, including employment and educational history, the platform provides tailored car loans and financing solutions with favorable terms and low-interest rates. Lendbuzz partners with auto dealerships to enhance their offerings, allowing them to serve a more diverse clientele and close additional business opportunities. The company emphasizes a streamlined documentation process, making it easier for clients to access and manage their loans.

ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

BioSight Ltd., established in 1999 and headquartered in Lod, Israel, is a biopharmaceutical company specializing in the development of innovative cancer-targeted pro-drugs. It focuses on creating non-toxic conjugates like its cytarabine-asparagine conjugate for treating acute myeloid leukemia patients worldwide. BioSight's proprietary technology, S2DOT™, enables targeted drug release inside cancer cells, minimizing systemic toxicity compared to conventional chemotherapy treatments.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Sol-Gel Technologies Ltd. is a clinical-stage specialty pharmaceutical company based in Ness Ziona, Israel, focused on the development and commercialization of topical dermatological drug products. The company utilizes a proprietary microencapsulation delivery system to create innovative formulations for treating various skin conditions. Its lead product candidates include Twyneo for acne vulgaris and Epsolay for papulopustular rosacea, both of which have completed Phase II clinical trials. Additionally, Sol-Gel is developing SGT-210, an epidermal growth factor receptor inhibitor for palmoplantar keratoderma and non-melanoma skin cancer, along with tapinarof and roflumilast for psoriasis and other dermatological conditions. The company also works on generic topical dermatological products, collaborating with partners such as Perrigo and Douglas Pharmaceuticals for development and commercialization efforts. Founded in 1997, Sol-Gel Technologies aims to address unmet needs in dermatology through its advanced drug delivery technologies.

Quiet Therapeutics Ltd. is a biotechnology company based in Ness Ziona, Israel, focused on discovering and developing innovative cancer therapies. Founded in 2009, the company employs its proprietary GAGomer technology, which includes RNA therapeutics and small molecule drugs, to specifically target tumor cells. This unique nanoparticle-based delivery system enhances the targeting capability of therapeutic agents, allowing for the effective treatment of cancer and inflammation. By concentrating on cell components that are challenging for conventional therapies to manage, Quiet Therapeutics aims to expand the repertoire of drug targets, ultimately improving patient outcomes and quality of life.

cCAM Biotherapeutics Ltd. is a clinical-stage biotechnology company based in Misgav, Israel, focused on the discovery and development of innovative immunotherapies for cancer treatment. The company is developing CM-10, an immunomodulatory antibody designed to enhance the immune system's ability to target and attack tumors by binding to CEACAM1, a protein that cancer cells exploit to evade immune responses. cCAM's lead therapeutic candidate, CM-24, is a humanized anti-CEACAM1 monoclonal antibody aimed at treating advanced and recurrent cancers, including melanoma, non-small-cell lung cancer, bladder, gastric, colorectal, and ovarian cancers. Established in 2010, cCAM Biotherapeutics aims to provide effective treatment options for patients facing various malignancies.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.